Topic: Gilead Sciences Inc.

Aurobindo uses patent pool for generic AIDS drugs

Reuters US Online Report Health News - 121 days ago
LONDON (Reuters) - India's Aurobindo Pharma has become the first major generic drugmaker to join a patent pool designed to make HIV/AIDS treatments more widely available to the poor, paving the way for it to sell cheap medicines in many countries.The Medicines ...
Read More...

Licensing deal to boost HIV drug access

AFP Global Edition - 212 days ago
US pharmaceutical giant Gilead Sciences and an NGO called the Medicines Patent Pool announced a deal on Tuesday aimed at boosting access to HIV drugs in poorer countries through generic manufacturing.The HIV medicines tenofovir and emtricitabine, as well as two drugs that ...
Read More...

Gilead No Longer a Leader

Barron's - 529 days ago
Gilead Sciences (GILD: GILEAD SCIENCES, WHICH WAS riding high until calendar 2009, began facing various issues in 2010 related to competitive pressures to its HIV franchise, its intellectual-property duration, pricing and recent health-care reforms. The company's performance in second-quarter calendar 2010 was ...

Gilead Sciences Seen Range-Bound

Barron's - 595 days ago
Nasdaq) By Wedbush Securities ($36.08, June 23, 2010). WE BELIEVE THE KEY events for Gilead Sciences (ticker: GILD) are the upcoming Btripla versus Atripla data (AIDS Congress, Vienna, July 18-23) and second-quarter earnings (late July), from which the Street will look for ...

Gilead Shares Face Continued Pressure

Barron's - 666 days ago
GILD) initiated two Phase III studies of the Quad regimen, timing and design as expected.. We anticipate top-line data release on the primary endpoint around year-end 2011 or early 2012, for potential launch around year-end 2012 or early 2013. We note that ...

U.S. Food and Drug Administration Approves Viread for Chronic Hepatitis B in Adults

Drugs.com - 1276 days ago
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B, a serious liver disease caused by the hepatitis B virus (HBV). Viread is ...